Abstract:The drugs against "Undruggable" targets remain an enormous challenge in drug discovery. Aptamers are used to address the ligand deficiency and isolate the anti‐c‐Myc aptamer. The aptamer‐based PROTAC that efficiently degrades c‐Myc (ProMyc) is developed. Based on the aptamer (PA1) delivery system, circular PA1‐ProMyc displays powerful antitumor activity in the tumor model, offering a potential degrader for intractable targets. Targeting "undruggable" targets with intrinsically disordered structures is of great significance for the treatment of disease. The transcription factor c‐Myc controls global gene expression and is an attractive therapeutic target for multiple types of cancers. However, due to the lack of defined ligand binding pockets, targeted c‐Myc have thus far been unsuccessful. Herein, to address the dilemma of lacking ligands, an efficient and high throughput aptamer screening strategy is established, named polystyrene microwell plate‐based systematic evolution of ligands by exponential enrichment (microwell‐SELEX), and identify the specific aptamer (MA9C1) against c‐Myc. The multifunctional aptamer‐based Proteolysis Targeting Chimeras (PROTAC) for proteolysis of the c‐Myc (ProMyc) is developed using the aptamer MA9C1 as the ligand. ProMyc not only significantly degrades c‐Myc by the ubiquitin‐proteasome system, but also reduces the Max protein, synergistically inhibiting c‐Myc transcriptional activity. Combination of the artificial cyclization and anti‐PD‐L1 aptamer (PA1)‐based delivery system, circular PA1‐ProMyc chimeras achieve tumor regression in the xenograft tumor model, laying a solid foundation for the development of efficacious c‐Myc degrader for the clinic. Therefore, this aptamer‐based degrader provides an invaluable potential degrader in drug discovery and anti‐tumor therapy, offering a promising degrader to overcome the challenge of targeting intractable targets.

Wnt5a/Ror2-induced Upregulation of Xpapc Requires Xshca.

Regulation of Cellular Signaling with an Aptamer Inhibitor to Impede Cancer Metastasis.

Selective Anti-melanoma Effect of Phosphothioated Aptamer Encapsulated by Neutral Cytidinyl/Cationic Lipids

XBP1s Activates METTL3/METTL14 for ER-phagy and Paclitaxel Sensitivity Regulation in Breast Cancer

RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule

Selective inhibition of cancer cell migration using a pH-responsive nucleobase-modified DNA aptamer

Anti-c-MET Fab-Grb2-Gab1 Fusion Protein-Mediated Interference of c-MET Signaling Pathway Induces Methuosis in Tumor Cells

A Stapled Peptide Inhibitor of METTL3-METTL14 for Cancer Therapy

A phosphatase-recruiting bispecific antibody-aptamer chimera for enhanced suppression of tumor growth

Selective and Orally Bioavailable c-Met PROTACs for the Treatment of c-Met-Addicted Cancer

Antitumor Effect of Anti‐c‐Myc Aptamer‐Based PROTAC for Degradation of the c‐Myc Protein

Cooperatively Designed Aptamer-PROTACs for Spatioselective Degradation of Nucleocytoplasmic Shuttling Protein for Enhanced Combinational Therapy

Engineering Aptamers with Selectively Enhanced Biostability in the Tumor Microenvironment

Bi-specific Aptamers Mediating Tumor Cell Lysis

A Bispecific Chimeric Aptamer Design Platform Based on c‐MET Aptamer with a Replaceable Redundant Region

Making Aptamers More Antibody-like: Targeting AXL in Vivo Using a Bottlebrush Polymer-Conjugated Aptamer

Structural insight into the macrocyclic inhibitor TPX-0022 of c-Met and c-Src

A Stapled Peptide Inhibitor Targeting the Binding Interface of N6‐Adenosine‐Methyltransferase Subunits METTL3 and METTL14 for Cancer Therapy

Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin

Engineering Polymeric Aptamers For Selective Cytotoxicity

Reversing MET‐Mediated Resistance in Oncogene‐Driven NSCLC by MET‐Activated Wnt Condensative Prodrug